Individuals with chronic tic disorders (CTDs) frequently describe aversive subjective sensory sensations that precede their tics. The first aim of the present study was to explore the psychometric properties of a standardized self-report measure to assess premonitory urges in CTDs, The Premonitory Urge for Tics Scale (PUTS), by replicating the analyses of Woods et al. (J Dev Behav Pediatr 26:397-403, 2005) using a sample twice the size of theirs. The second aim was to conduct an exploratory factor analysis of the PUTS. Eighty-four youth with CTDs, recruited from a pediatric OCD and tic specialty clinic, completed the PUTS while their caregivers completed The Parent Tic Questionnaire (PTQ) and a demographic measure. Consistent with (Woods et al. J Dev Behav Pediatr 26:397-403, 2005), the PUTS was found to be internally consistent (α = 0.82) and significantly correlated with overall tic severity as measured by the PTQ (r = 0.24, p < 0.05) as well as the PTQ number (r = 0.34, p < 0.01) and intensity (r = 0.24, p < 0.05) subscales. A factor-analysis of the PUTS revealed a two-factor solution with one factor capturing the quality of premonitory sensations while the other factor assessed the overall intensity of the urges. These results support the use of the PUTS in reliably measuring premonitory urges, particularly in children over the age of 10 years. Additionally, these findings highlight that urges are uniformly reported across gender and age and are more closely associated with number of tics than the frequency or intensity of tics.

Aims: Fear of hypoglycaemia (FOH) can contribute to impaired sleep for adults with type 1 diabetes (T1D) and parents of children with T1D, although it is unknown how FOH may affect sleep for adolescents with T1D. This study examines the relationship between adolescent FOH and sleep and assessed the influences of continuous glucose monitor (CGM) and insulin pump use. Methods: Adolescents ages 14-18 years with T1D completed questionnaires evaluating FOH (Child Hypoglycemia Fear Survey) and sleep (Pittsburgh Sleep Quality Index, PSQI). Analyses included linear and logistic regression, t-tests and Fisher's exact tests. Results: Participants included 95 adolescents (52 female) with a median (IQR) age of 16.5 (15.3-17.7) years and a T1D duration of 5.7 (2.5-9.6) years. Analyses showed increased FOH-Worry subscale scores were associated with reduced sleep duration (β = −0.03, p = 0.042, adjusting for BMI z-score, race and ethnicity) and increased sleep disturbances (OR = 1.1, p = 0.038, adjusting for race and ethnicity). Frequent CGM users had longer sleep duration (average 7.5 h) compared with infrequent or non-CGM users (average = 6.8 h; p = 0.029), and pump users had overall improved sleep health as determined by PSQI score (p = 0.019). Technology use did not have significant interactions in the relationships between FOH and sleep duration or sleep disturbances. Conclusions: Worrying about hypoglycaemia was associated with impaired sleep for adolescents with T1D. Diabetes technology users have some sleep improvements, but CGM and pump use do little to alter the relationship between FOH and sleep outcomes.

No abstract

Traditional behavioral treatments for tic disorders in youth require 8 sessions delivered over 10 weeks. Treatment duration represents a major barrier for patients and families, hinders direct comparisons between behavioral treatment and front line medication, and may motivate front line pharmacotherapy in place of behavioral interventions. The current case series describes an accelerated rapid-response behavioral triage for tics (RRBTT) and treatment outcomes. A retrospective chart review was conducted on clinically referred patients (n ϭ 10). The RRBTT consisted of 8 sessions delivered over 2 weeks, with a 1-month booster and evaluation session. Primary outcome measures were completed by the therapist conjointly with the parent and child at baseline, 1 and 2 weeks after beginning treatment, and 1 month after completing treatment. On average, youth experienced significant reductions (17.9%) in the Yale Global Tic Severity Scale after 1 week of treatment and (40.8%) by the 2-week posttreatment assessment (effect size ϭ .76). Posttreatment improvements in outcomes maintained at the 1-month follow-up with no additional treatment. Half of the patients (n ϭ 5) were rated as treatment responders, with 4 additional patients rated as receiving some benefit. The current findings highlight the flexible administration of an accelerated behavioral treatment, suggesting that the RRBTT may be effective in treating children and adolescents with tic disorders. These preliminary findings suggest the need for large-scale randomized controlled trials of RRBTT.